Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
Marc S. Sabatine(Brigham and Women's Hospital), Terje R. Pedersen(University of Oslo), Anthony Keech(Heidelberg University), Armando Lira Pineda(Amgen (United States)), Narimon Honarpour(Center for Global Development), Yehuda Handelsman(Tarzana Treatment Centers), Robert P. Giugliano(Thrombolysis in Myocardial Infarction Study Group), Basil S. Lewis(Technion – Israel Institute of Technology), Peter S. Sever(Imperial College London), Ioanna Gouni‐Berthold(University of Cologne), Prakash Deedwania(San Francisco VA Medical Center), Lawrence A. Leiter(St. Michael's Hospital), Sabina A. Murphy(Brigham and Women's Hospital), Stephen D. Wiviott(Brigham and Women's Hospital), Gaetano Maria De Ferrari(University of Pavia), Julia Kuder(Brigham and Women's Hospital)
Cited by 595
Related Papers
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
|New England Journal of Medicine|2017|6k